Background Henoch–Sch枚nlein purpura (HSP) can progress to Henoch–Sch枚nlein purpura nephritis (HSPN), and the most effective management remains unclear. Our aim was to evaluate the efficacy of mycophenolate mofetil (MMF) for treating pediatric patients with HSPN and nephrotic-range proteinuria.